" class="no-js "lang="en-US"> Diseases Archives - Page 103 of 139 - Medtech Alert
Monday, May 04, 2026

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Vinehealth Raises $5.5m to Improve the Quality of Life and Survival of Cancer Patients

Today, Vinehealth announces it has raised $5.5m in seed funding. The round was led by […]

MHRA Approves Xevudy (sotrovimab), a COVID-19 Treatment Found to Cut Hospitalisation and Death by 79%

Another COVID-19 treatment, Xevudy (sotrovimab), has today been approved by the Medicines and Healthcare products […]

Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]

Aelis Farma Announces Good Results From its First Administration in Humans for AEF0217, its First Drug Candidate for the Treatment of Cognitive Disorders in Down Syndrome

AELIS FARMA, a biotechnology company specializing in the treatment of brain disorders, announces today that AEF0217 […]

Roche Has Rapidly Developed Additional Testing Options to Differentiate Mutations in the Omicron SARS-CoV-2 Variant

Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche […]

Acumen Diagnostics' PCR Capabilities to Tackle Omicron COVID-19 Variant

Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. (“Acumen Diagnostics” or the “Company”), a 51% […]

On Target Laboratories Announces FDA Approval of CYTALUX ™ (pafolacianine) Injection for Identification of Ovarian Cancer During Surgery

On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent imaging agents to target and […]

JOYSBIO's SARS-COV-2 Antigen Rapid Test Detects OMICRON Variant

JOYSBIO, one of the world’s leading manufacturers of lateral flow rapid tests, is proud to […]

Cue Health Confirms COVID-19 Tests Can Detect Omicron Variant

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it has completed an analysis […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more